XPD functions as a tumor suppressor and dysregulates autophagy in cultured HepG2 cells

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 1562-1568

  Zheng, Jian Feng ^a   Li, Lin Lin ^a   Lu, Juan ^b   Yan, Kun ^a   Guo, Wu Hua ^a   Zhang, Ji Xiang ^a,c  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Children Hospital   (China)

^c Jiangxi Province Key Laboratory of Molecular Medicine   (China)

Author keywords

Carcinoma; Hep G2 cells; Hepatocellular; Xeroderma pigmentosum group A protein

Indexed keywords

MICROTUBULE ASSOCIATED PROTEIN 1; PROTEIN P62; XERODERMA PIGMENTOSUM GROUP D PROTEIN; LIPOCORTIN 5; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; AUTOPHAGY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; GENE; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; XERODERMA PIGMENTOSUM GROUP D PROTEIN GENE; CFU COUNTING; GENETICS; HEP-G2 CELL LINE; IN VITRO STUDY; PHYSIOLOGY;

ANNEXIN A5; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; HEP G2 CELLS; HUMANS; IN VITRO TECHNIQUES; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEINS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84930660751     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894303     Document Type: Article

References (24)

1. Cheung R: Epidemiology and radiotherapy of hepatocellular carcinoma. Int J Cancer Clin Res, 2014; 1: 2
2. Osaki Y, Nishikawa H: Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res, 2015; 45: 59–74
3. Guo L-Y, Jin X-P, Niu W et al: Association of XPD and XRCC1 genetic polymorphisms with hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 2012; 13: 4423–26
4. Yuan T, Deng S, Liu H et al: Relationship between XRCC1 and XPD polymorphisms and the risk of the development of hepatocellular carcinoma: A case-control study. Exp Ther Med, 2012; 4: 285–90
5. Peng Q, Li S, Lao X et al: Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: A systematic review and meta-analysis. Medicine, 2014; 93: e330
6. Zhang R-C, Mou S-H: Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis. Tumor Biol, 2013; 34: 901–7
7. Long XD, Ma Y, Zhou YF et al: XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer, 2009; 9: 400
8. Ding H, Xu J-j, Huang Y et al: XPD could suppress growth of HepG2. 2.15 and down-regulate the expression of hepatitis B virus x protein through P53 pathway. Biochem Biophys Res Commun, 2012; 419: 761–67
9. Li Q, Wang G, Shan JL et al: MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol, 2010; 25: 164–71
10. Brosh Jr RM: DNA helicases involved in DNA repair and their roles in cancer. Nat Rev Cancer, 2013; 13: 542–58
11. Lee M-S, Liu C-Y, Su L et al: Polymorphisms in the nucleotide excision repair genes, ERCC1 and ERCC2/XPD and carcinogen DNA adducts in human lung. Cancer Research, 2012; 72: 4479
12. Tengstrom M, Mannermaa A, Kosma V-M et al: MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen. Acta Oncol, 2014; 53: 769–75
13. Kumar A, Pant MC, Singh HS, Khandelwal S: Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population. Mutat Res, 2012; 729: 24–34
14. Xue H, Lu Y, Lin B et al: The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and metaanalysis. PloS One, 2012; 7: e43431
15. Mehrzad J, Hashemi M, Jamshidi M et al: Decreased expression of DNA repair genes (XRCC1 and XPD/ERCC2) in colorectal cancer in Iranian patients. International Journal of Biosciences (IJB), 2014; 4: 197–205
16. Duan X-L, Gong H, Zeng X-T et al: Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 2012; 13: 3299–303
17. Avan A, Pacetti P, Reni M et al: Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer, 2013; 133: 1016–22
18. Chang C-H, Wang R-F, Tsai R-Y et al: Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res, 2009; 29: 3903–7
19. Yue A-M, Xie Z-B, Guo S-P et al: Implication of polymorphisms in DNA repair genes in prognosis of hepatocellular carcinoma. Asian Pac J Cancer Prev, 2013; 14: 355–58
20. Wang H-Y, Xiong G-F, Zhang J-X et al: The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells. Med Oncol, 2012; 29: 161–67
21. Peng Y-F, Shi Y-H, Shen Y-H et al: Promoting colonization in metastatic HCC cells by modulation of autophagy. PloS One, 2013; 8: e74407
22. Pankiv S, Clausen TH, Lamark T et al: p62/SQSTM1 binds directly to Atg8/ LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem, 2007; 282: 24131–45
23. Lazova R, Camp RL, Klump V et al: Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res, 2012; 18: 370–79
24. Hur CJ, Kim JM, Yang KH et al: Poster Session: PS 0950; Liver: The autophagy- related marker P62 is useful for diagnosis in human hepatocellular carcinoma. Institute of Medicine Conference Proceedings, 2014; 2014: 562